These Analysts Slash Their Forecasts On GeneDx After Q4 Results

GeneDx Holdings Corp (NASDAQ: WGS) reported better-than-expected fourth-quarter financial results on Monday.

Benzinga • 11 hours ago

GeneDx: The Growth Story Isn't Dead, It's Changing (Rating Upgrade)

GeneDx (WGS) is upgraded to 'Buy' as valuation resets and operational improvements support a more realistic growth outlook. Per my DCF model, WGS now targets 25% CAGR and 10% free cash flow margins, with potential to reach 14% FCF margin, making its valuation less stretched. Management plans to nearly triple its commercial footprint in 2026, prioritizing growth capture over near-term margins and signaling a ramp toward 2027 acceleration.

Seeking Alpha • 16 hours ago

GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript

GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 23, 2026

GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.

Business Wire • Feb 23, 2026

INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.

Business Wire • Feb 23, 2026

GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Beat Estimates

GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.7 per share a year ago.

Zacks Investment Research • Feb 23, 2026

TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World's Most Influential Leaders in Health

GAITHERSBURG, Md.--(BUSINESS WIRE)--TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List.

Business Wire • Feb 11, 2026

Polen 5Perspectives Small Growth Portfolio Performance & Attribution

The Portfolio returned -1.3% gross and -1.5% net compared to the 1.2% return of the Russell 2000 Growth Index. Bloom Energy announced better than expected results with added optimism from a $5B partnership with Brookfield as the preferred onsite power provider. GeneDx delivered better-than-expected results—including raised full-year guidance—driven by a significant year-over-year increase in high value testing volumes.

Seeking Alpha • Feb 5, 2026

GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026.

Business Wire • Feb 3, 2026

Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. If you currently own GeneDx stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your le.

Business Wire • Jan 15, 2026